Suppr超能文献

根治性膀胱切除术时行尿道切除术治疗非转移性膀胱尿路上皮癌:一项协作多中心研究。

Urethrectomy at the time of radical cystectomy for non-metastatic urothelial carcinoma of the bladder: a collaborative multicenter study.

机构信息

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

出版信息

World J Urol. 2022 Jul;40(7):1689-1696. doi: 10.1007/s00345-022-04025-z. Epub 2022 May 20.

Abstract

INTRODUCTION

The optimal management of the urethra in patients planned for radical cystectomy (RC) remains unclear. We sought to evaluate the impact of urethrectomy on perioperative and oncological outcomes in patients treated with RC for non-metastatic urothelial carcinoma of the bladder (UCB).

MATERIALS AND METHODS

We assessed the retrospective data from patients treated with RC for UCB of five European University Hospitals. Associations of urethrectomy with progression-free (PFS), cancer-free (CSS), and overall (OS) survivals were assessed in univariable and multivariable Cox regression models. We performed a subgroup analysis in patients at high risk for urethral recurrence (UR) (urethral invasion and/or bladder neck invasion and/or multifocality and/or prostatic urethra involvement).

RESULTS

A total of 887 non-metastatic UCB patients were included. Among them, 146 patients underwent urethrectomy at the time of RC. Urethrectomy was performed more often in patients with urethral invasion, T3/4 tumor stage, CIS, positive frozen section analysis of the urethra, and those who received neoadjuvant chemotherapy, underwent robotic RC, and/or received an ileal conduit urinary diversion (all p < 0.001). Estimated blood loss and the postoperative complication rate were comparable between patients who received an urethrectomy and those who did not. Urethrectomy during RC was not associated with PFS (HR 0.83, p = 0.17), CSS (HR 0.93, p = 0.67), or OS (HR 1.08, p = 0.58). In the subgroup of 276 patients at high risk for UR, urethrectomy at the time of RC decreased the risk of progression (HR 0.58, p = 0.04).

CONCLUSION

In our study, urethrectomy at the time of RC seems to benefit only patients at high risk for UR. Adequate risk assessment of UCB patients' history may allow for better clinical decision-making and patient counseling.

摘要

简介

在计划接受根治性膀胱切除术 (RC) 的患者中,尿道的最佳处理方法仍不清楚。我们旨在评估在因非转移性膀胱尿路上皮癌 (UCB) 接受 RC 治疗的患者中,尿道切除术对围手术期和肿瘤学结果的影响。

材料和方法

我们评估了来自五家欧洲大学医院接受 RC 治疗 UCB 的患者的回顾性数据。在单变量和多变量 Cox 回归模型中,评估了尿道切除术与无进展生存 (PFS)、无癌症生存 (CSS) 和总体生存 (OS) 的相关性。我们在高危尿道复发 (UR) 患者亚组中进行了分析 (尿道浸润和/或膀胱颈部浸润和/或多灶性和/或前列腺尿道受累)。

结果

共纳入 887 例非转移性 UCB 患者。其中,146 例患者在 RC 时行尿道切除术。在有尿道浸润、T3/4 肿瘤分期、CIS、尿道冷冻切片分析阳性、接受新辅助化疗、行机器人 RC 治疗和/或接受回肠导管尿流改道的患者中,更常进行尿道切除术 (均 p<0.001)。接受尿道切除术和未接受尿道切除术的患者之间估计失血量和术后并发症发生率无差异。RC 时行尿道切除术与 PFS 无关 (HR 0.83,p=0.17)、CSS (HR 0.93,p=0.67) 或 OS (HR 1.08,p=0.58)。在 UR 高危的 276 例患者亚组中,RC 时行尿道切除术可降低进展风险 (HR 0.58,p=0.04)。

结论

在我们的研究中,RC 时行尿道切除术似乎仅使 UR 高危患者受益。对 UCB 患者病史进行充分的风险评估可能有助于更好地做出临床决策和患者咨询。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7162/9236994/9c81085fc71f/345_2022_4025_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验